Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.

Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD.

Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005.

2.

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.

Blázquez-Pérez A, San Miguel R, Mar J.

Pharmacoeconomics. 2013 Oct;31(10):919-31. doi: 10.1007/s40273-013-0080-3.

PMID:
24000086
3.

A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.

Westerhout K, Treur M, Mehnert A, Pascoe K, Ladha I, Belsey J.

J Med Econ. 2015;18(10):838-49. doi: 10.3111/13696998.2015.1044457. Epub 2015 Jul 6.

PMID:
25903830
4.

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.

Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.

JAMA. 2003 Jul 9;290(2):228-37.

PMID:
12851278
5.

Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.

Athanasakis K, Ferrante SA, Kyriopoulos II, Petrakis I, Hill M, Retsa MP, Kyriopoulos J.

Clin Ther. 2015 Jul 1;37(7):1529-40. doi: 10.1016/j.clinthera.2015.05.003. Epub 2015 May 29.

PMID:
26031617
6.

Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.

Bock JA, Fairley KJ, Smith RE, Maeng DD, Pitcavage JM, Inverso NA, Williams MS.

Public Health Genomics. 2014;17(5-6):306-19. doi: 10.1159/000365939. Epub 2014 Sep 18.

7.
8.

[Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].

Buti M, Gros B, Oyagüez I, Andrade RJ, Serra MA, Turnes J, Casado MA.

Farm Hosp. 2014 Sep 16;38(5):418-29. doi: 10.7399/fh.2014.38.5.7640. Spanish.

9.

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators..

Health Technol Assess. 2006 Jul;10(21):1-113, iii.

10.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

11.

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.

Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK.

Ann Intern Med. 2015 Mar 17;162(6):407-19. doi: 10.7326/M14-1152.

PMID:
25775313
12.

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY.

Ann Intern Med. 2015 May 5;162(9):619-29. doi: 10.7326/M14-1313.

13.

Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.

Fraser I, Burger J, Lubbe M, Dranitsaris G, Sonderup M, Stander T.

Pharmacoeconomics. 2016 Apr;34(4):403-17. doi: 10.1007/s40273-015-0356-x.

PMID:
26666639
14.

Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.

Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD.

Ann Intern Med. 2014 Oct 21;161(8):546-53. doi: 10.7326/M14-0602.

15.

Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB.

Pharmacoeconomics. 2009;27(4):341-54. doi: 10.2165/00019053-200927040-00006.

PMID:
19485429
16.

Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.

Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG.

JAMA Intern Med. 2016 Jan;176(1):65-73. doi: 10.1001/jamainternmed.2015.6011.

17.

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.

J Med Econ. 2014 Jan;17(1):65-76. doi: 10.3111/13696998.2013.860033. Epub 2013 Nov 18.

PMID:
24160335
18.

Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J.

Pharmacoeconomics. 2004;22(4):257-65.

PMID:
14974875
19.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
20.

Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.

Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME.

J Gastroenterol Hepatol. 2013 Apr;28(4):707-16. doi: 10.1111/jgh.12041.

PMID:
23173753

Supplemental Content

Support Center